IsoRay (ISR) Shares To Appreciate

Analysts at C.K. Cooper have reiterated their Buy rating on medical supplies manufacturer IsoRay

. The company’s results for the quarter ended March 31st showed a loss of $0.05 per share on revenues of $1.20 million. This was lower than C.K. Cooper’s estimates for a loss of $0.03 on revenues of $1.47 million. The price target has been set at $1.70 and the Buy rating has been maintained, given IsoRay’s price appreciation prospects. Revenues are expected to stabilize on Cesium sales. The company is evaluating devices for wider use of Cesium, as well as non-medical uses for the product.